Bridget Clausen refers to her seven grandchildren and three great-grandchildren as "the love of my life." She treasures each of them and is proud to have a great-granddaughter named after her. The joy of a namesake is especially sweet, because when Bridget learned her granddaughter was pregnant, she wasn't sure she would be here to meet the baby.
At that time, Bridget was being treated for melanoma that had spread to several places in her body. Her treatment choices were dwindling. She decided to go to Mayo Clinic in Rochester, Minnesota, to see if doctors could offer any other options. As a result of that visit, Bridget enrolled in a clinical trial of a new drug. It turned out to be the answer she needed.
The drug, now available under the brand name Keytruda, was approved by the Food and Drug Administration in December 2015 as a first-line treatment for advanced melanoma. Interestingly, the foundation of the drug's development began in a Mayo Clinic lab more than 15 years ago. In Bridget's case, it successfully shrunk her tumors and stopped the spread of cancer. It also gave her the opportunity to meet her new great-granddaughter.